托法替布作为住院难治性重度溃疡性结肠炎挽救治疗的GETAID队列研究
本研究为GETAID多中心观察性研究,纳入55例因溃疡性结肠炎(UC)重度发作住院且既往多种药物失败的患者,评估托法替布挽救治疗的无结肠切除生存率及安全性。中位随访6.5个月,3个月和6个月无结肠切除生存率分别为78.9%和73.6%,第6周临床应答率60%、临床缓解率45.5%,未观察到死亡、静脉血栓或主要心血管不良事件。
要点
- 托法替布用于住院难治性重度UC挽救治疗,3个月无结肠切除生存率78.9%。
- 第6周临床应答率60%、临床缓解率45.5%,起效较快。
- 安全性方面无死亡、无静脉血栓或主要心血管不良事件,需警惕老年患者带状疱疹。
核心结论
- 托法替布在因UC重度发作住院且既往多种药物失败的患者中显示出有前景的挽救治疗效果,但需对照试验进一步验证。
研究设计与样本
- GETAID多中心观察性研究,在14个中心回顾性和前瞻性收集资料,共纳入55例因UC重度发作住院的患者。
主要发现
- 中位随访6.5个月(IQR 3-12.3),3个月和6个月无结肠切除生存率分别为78.9%(95%CI 68.5-90.9)和73.6%(95%CI 61.9-87.3)。
- 第6周临床应答率60%、临床缓解率45.5%、无激素临床缓解率37.5%;第14周分别为41.8%、34.5%、32.7%。
- 安全性方面无死亡,3例因不良事件停用托法替布,2例60岁以上患者发生带状疱疹感染,无静脉血栓或主要心血管不良事件。
临床怎么用
- 对于因重度UC发作住院且既往 steroids 和抗TNF药物等多种治疗失败的患者,托法替布可作为快速起效的挽救治疗选项。
- 使用托法替布时需关注不良事件,尤其60岁以上患者应警惕带状疱疹感染。
局限性
- 本研究为观察性研究,样本量55例,需对照试验进一步验证托法替布的疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Up to 25% of patients with ulcerative colitis (UC) will require hospitalization for severe flare. In patients hospitalised for severe flare, who previously experienced multiple drug failures, including steroids and anti-TNF agents, new quick-acting medical options are needed. Tofacitinib is effective in refractory UC and has a rapid onset of action. AIM: To evaluate effectiveness and safety of tofacitinib as rescue therapy in patients hospitalised for UC flare. METHODS: We conducted an observational and multicentre study with both retrospective and prospective collections in 14 GETAID centres. The primary objective was to assess the survival without colectomy following tofacitinib initiation in patients hospitalised for a UC flare. We determined rates of clinical response, clinical remission, and steroid-free clinical remission at week 6 and week 14 and safety. RESULTS: Fifty-five patients were included (49 with prior infliximab failure and 19 previously exposed to ciclosporin). With a median follow-up of 6.5 months (interquartile range [IQR] [3-12.3]), rate of colectomy-free survival was estimated at 78.9% (95 CI [68.5-90.9]) and 73.6% (95 CI [61.9-87.3]) at 3 and 6 months, respectively. Rates of clinical response, clinical remission and steroid-free clinical remission were 60%, 45.5% and 37.5% at week 6 and 41.8%, 34.5% and 32.7% at week 14. Regarding safety, no death was observed, three patients withdrew tofacitinib due to adverse events. Two herpes zoster infections occurred in patients aged over 60 years old. No venous thrombotic or major adverse cardiovascular events occurred. CONCLUSION: Tofacitinib appears as a promising option in patients hospitalised with a UC flare but needs further validation in controlled trials.
引用
- Uzzan M, Bresteau C, Laharie D, et al. Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort. Aliment Pharmacol Ther. 2021. PMID: 34151448. doi:10.1111/apt.16463
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。